Copiktra (duvelisib) / Verastem, CSPC Pharma, Secura Bio, Sanofi, Yakult Honsha - LARVOL DELTA

Characterization of pityriasis rubra pilaris with hematological malignancies: Paraneoplastic disease and targeted therapy reactions (ASH 2025) - "The ALL patient was related to ponatinib, the non-Hodgkin's lymphoma case was related to copanlisib, 2 CLL patients were related to duvelisib, and 2 CLL were related to idealisib...With regards to paraneoplastic treatment, topical treatment included corticosteroids, emollients, topical urea, retinoids, and fluorouracil. Systemic treatments included methotrexate, systemic corticosteroids, and phototherapy...Specialists should maintain a high index of suspicion for PRP as a paraneoplastic signal or drug-related adverse event. Future studies are needed to elucidate such presentations and guide management."

Chronic Lymphocytic Leukemia • Dermatology • Dermatopathology • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Lymphoma • Multiple Myeloma • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma • Oncology

Patient assistance for drug cost sharing: Highlighting the variability across pharmaceutical manufacturers of specialty oral anticancer medications for blood cancers (ASH 2025) - "Two of the three manufacturers that did not offer a PAP had discontinued their free-drug program (idelalisib and duvelisib) whereas one never had a free drug program (revumenib). All SOAMs for blood cancer have copay assistance programs for commercially insured and nearly all directly provide free-drugs for select individuals. However, eligibility by insurance type, income level, and associated documentation requirements vary considerably across manufacturers. Future work needs to evaluate whether this variability results in inequitable access across SOAM agents within same indication."

Clinical • Drug cost • HEOR • Hematological Malignancies • Oncology • Oral Cancer

Genetic deletion of vasoactive intestinal peptide (VIP) and PI3K signaling pathways impair CAR T cell function (ASH 2025) - "During expansion, cells were cultured in the presence or absence of the PI3Kδ/γ inhibitor, Duvelisib... Dual targeting of PI3Kδ/γ and VIP signaling enhances CAR T cell memory phenotype and mitochondrial metabolic fitness, promoting a less exhausted and more quiescent T cell state. These in vivo results demonstrate that infusion of greater frequencies of memory CAR T cells with greater reliance on oxidative phosphorylation were insufficient to achieve durable tumor control in a solid tumor model, highlighting the critical role of the tumor microenvironment and endogenous immune cells in CAR T cell efficacy. The genetic absence of VIP/VPAC in the context of PI3K inhibitors may have a more profound effect on T cell survial than pharmacological inhibition of VPAC and PI3K."

CAR T-Cell Therapy • IO biomarker • Hematological Malignancies • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • CD4 • CD8 • IL2 • PIK3CD

primary analysis of Phase ib trial of duvelisib for cytokine release syndrome prophylaxis in patients undergoing chimeric antigen receptor T cell therapy for non-hodgkins lymphoma (ASH 2025) - P1 | "Diagnoses included DLBCL (n = 20), MCL (6), FL (1) and PBMCL (1).Patients received axi-cel (22), liso-cel (14), brexu-cel (5) and tisa-cel (1).40 patients were evaluable for the primary endpoint. Duvelisib is also associated with delayed onset of CRS, which may enableoutpatient administration of CAR T-cells. Though limited by clinical heterogeneity, ORR and 1-year PFSare comparable to prior reports, suggesting duvelisib does not significantly inhibit CAR T-cell function"

CAR T-Cell Therapy • Clinical • Cytokine release syndrome • P1 data • Diffuse Large B Cell Lymphoma • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Septic Shock • CD8 • HEY1 • IL6

Representation of older adults in registrational trials associated with therapeutic approvals in follicular lymphoma (ASH 2025) - "Of the drugs approved, 2 were bispecific antibodies (BsAb,epcoritamab, mosunetuzumab), 3 were chimeric antigen receptor-T (CAR-T) products (lisocabtagene,axicabtagene, tisagenleucel), 3 were PI3K inhibitors (umbralisib, copanlisib, duvelisib), 2 were monoclonalantibodies (obinutuzumab with chemotherapy, obinutuzumab with bendamustine), and 1 each ofselective EZH2 inhibitor (tazemetostat), immunomodulator (lenalidomide with rituximab), and BTKinhibitor (zanubrutinib). Most registrational trials for FL do report a subgroup of OA, although inclusion of OAremains suboptimal at 37%. Representation and reporting of pts≥ 75 yrs is significantly low at only 8%,despite this group representing 20% pts at diagnosis. Reporting of trials should include and distinguishpts ≥65 yrs and ≥75 yrs for subgroup analyses."

Clinical • Follicular Lymphoma • Geriatric Disorders • Hematological Malignancies • Lymphoma

Duvelisib in patients with relapsed/refractory peripheral T-cell lymphoma: Final results from the phase 2 PRIMO trial - impact of prior therapy and expanded safety analysis (ASH 2025) - P2, P3 | "Current single agent therapies deliver modest overall response rates (ORR), typically <30%(except brentuximab vedotin [BV] in anaplastic large cell lymphoma; ALCL). These data support the tolerability of this regimenin R/R PTCL despite a higher starting dose. Efficacy in the AITL group stands out; based on these results,the sponsor has initiated a randomized phase 3 study to investigate duvelisib in a homogeneouspopulation of R/R nodal T-follicular helper cell lymphoma (NCT06522737; TERZO™)."

Clinical • P2 data • Chronic Lymphocytic Leukemia • Follicular Lymphoma • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Immunology • Leukemia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • Small Lymphocytic Lymphoma • T Cell Non-Hodgkin Lymphoma • Thrombocytopenia • PIK3CG • TINCR

Roginolisib (IOA-244), an orally bioavailable, selective PI3Kδ inhibitor, in combination with venetoclax and rituximab in patients with relapsed chronic lymphocytic leukemia (CLL) (ASH 2025) - P1, P1/2 | "Our group has previously shown promising clinical activity with the combination of thefirst-generation PI3K inhibitor duvelisib and venetoclax, albeit hampered by PI3Ki-related adverse events.In contrast to the first generation PI3K inhibitors, roginolisib is a novel, oral, non-ATP competitive,allosteric small molecule inhibitor of PI3Kδ with a unique safety profile. At the timeof submission of the Abstract , the first dose level cohort of patients in Phase 1 was enrolled.ConclusionsFirst generation PI3K inhibitors have had limitations in patients with hematologic malignancies. Novelnon-ATP competitive, highly selective inhibitors may provide a tailored safe therapy targeting a keybiologic pathway in CLL and enable combinations with standard of care treatments in relapsed/refractoryCLL."

Clinical • Combination therapy • Chronic Lymphocytic Leukemia • Follicular Lymphoma • Lymphoma • Solid Tumor • PIK3CD

A decade of progress: A comparative analysis of real-world survival in chronic lymphocytic leukemia across therapeutic eras (ASH 2025) - "The ECOG E1912 randomized study demonstratedsuperior overall survival of ibrutinib-based therapy compared to chemoimmunotherapy with fludarabine,cyclophosphamide, and rituximab (FCR)...For these cohorts, 5-year all-cause mortality was comparedbetween the pre-2015 and 2015-2020 groups, and 2-year all-cause mortality was compared between thepre-2015 and post-2020 groups.Second, to directly compare treatment effectiveness, patients who received systemic therapy werestratified into two cohorts based on the class of agent received, irrespective of the treatment date:Chemoimmunotherapy (CIT): Regimens including FCR, BR, Fludarabine with Rituximab,Chlorambucil ± Obinutuzumab, and Alemtuzumab-based treatments.Novel Targeted Therapy: Regimens including covalent BTK inhibitors (Ibrutinib, Acalabrutinib,Zanubrutinib), BCL-2 inhibitor Venetoclax (± Rituximab or Obinutuzumab), and PI3K inhibitors(Idelalisib, Duvelisib).For these treatment-regimen cohorts, 10-year outcomes..."

Clinical • Real-world • Real-world evidence • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia

Efficacy and safety of duvelisib combined with chidamide as first-line treatment for angioimmunoblastic T-cell lymphoma (AITL) (ASH 2025) - P2 | "The preliminary results of the study indicate that the combination of targeted therapy usingDUV and chidamide and chemotherapy shows good efficacy and manageable safety. profile in newlydiagnosed AITL, warranting further exploration."

Clinical • Hematological Malignancies • Infectious Disease • Leukopenia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • Respiratory Diseases • T Cell Non-Hodgkin Lymphoma

Favorable safety and efficacy in a phase II trial using duvelisib maintenance after autologous stem cell transplant in T-cell and B-cell non-Hodgkin lymphomas (ASH 2025) - "In patients withTCL, duvelisib maintenance yielded promising disease control and compares favorably to historicaloutcomes in this high-risk population. Given the promising results, a larger multicenter phase 3 trial iswarranted."

Clinical • P2 data • B Cell Non-Hodgkin Lymphoma • Febrile Neutropenia • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Otorhinolaryngology • Peripheral T-cell Lymphoma • Pneumonia • Respiratory Diseases • Sinusitis • T Cell Non-Hodgkin Lymphoma • Transplantation

MYC-dependent permissiveness of PI3K hyperactivation renders metabolic vulnerability in R/R b-ALL (ASH 2025) - "Our study suggests that combining the FDA-approvedPI3Kγ/δ inhibitor, Duvelisib, with CAR-T therapy holds significant promise for the treatment of R/R B-ALL.Furthermore, we identified NADH accumulation as a key metabolic vulnerability in R/R B-ALL, renderingthese cells susceptible to reductive stress enhancing treatment and glutamine derivation. Notably,Pegaspargase is particularly important for treating R/R B-ALL, and here we report that combiningPegaspargase with a potent complex I inhibitor IACS, which impairs NADH oxidation process, exhibitssignificant therapeutic effects on mice with PI3KhiMYCamp B-ALL.ResultsBy analyzing cancer cohorts based on transcription profiles indicative of PI3K and MYC activity, we foundunlike their established roles as individual prognostic indicators in other cancers, neither PI3K nor MYCactivity alone robustly predicts B-ALL prognosis...Additionally,PI3KhiMYCamp serves as a prognostic marker, identifying B-ALL patients with poor outcomes...."

IO biomarker • MYC • PIK3CG

Integrated single-cell RNA sequencing and TCR profiling identifies immune drivers of severe early toxicity in CLL patients treated with idelalisib (ASH 2025) - "PI3K inhibitors, such as idelalisib and duvelisib, have demonstrated efficacy in relapsed/refractory chroniclymphocytic leukemia (CLL) but severe autoimmune toxicities limit their clinical use. This aligns with prior findings that CD4+ Tcells reprogram metabolism and promote Th17 responses via HIF-1α and GLUT1 in rheumatoid arthritis,an autoimmune disease.Overall, our findings suggest idelalisib-induced toxicity develops in patients with a predisposed immunemicroenvironment with sustained higher clonal diversity and metabolic-immune dysregulation, leading tothe expansion of CD8+ and CD4+ T cell clones with TH17/TH1 polarization, cytotoxicity, and migratoryphenotypes. These insights into PI3Kδ inhibitor-induced toxicity may suggest potential targets to mitigateadverse effects."

Clinical • Chronic Lymphocytic Leukemia • Hematological Malignancies • Immunology • Inflammatory Arthritis • Leukemia • Rheumatoid Arthritis • Rheumatology • Transplant Rejection • ACLY • BACH2 • CD4 • CD8 • CXCR3 • EGR1 • FOXP3 • GZMB • HIF1A • IFNG • IFNGR1 • IL7R • IRF1 • JAK2 • LDHA • MTHFD2 • PIK3CD • PRF1 • RAC2 • SLC2A1 • STAT1 • TBX21 • TMSB4X • ZEB1

Relative Efficacy of Systemic Treatments for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: A Network Meta-Analysis According to 17p Deletion/TP53 Mutations (ASH 2024) - "Ibrutinib was used as reference treatment.Results : Twelve trials involving 4,437 patients and 13 treatment options were included in the meta-analysis : three Bruton tyrosine kinase (BTK) inhibitors (ibrutinib, acalabrutinib, and zanubrutinib), two BTK inhibitors combined with other treatments (ibrutinib plus rituximab plus bendamustine [RB] and ibrutinib plus rituximab), two phosphoinositide 3-kinase (PI3K) inhibitors (idelalisib and duvelisib), three PI3K inhibitors combined with other treatments (idelalisib plus ofatumumab, idelalisib plus RB, idelalisib plus rituximab), three anti-CD20-based treatment (RB, ofatumumab, and rituximab), and one BCL-2 inhibitor (venetoclax plus rituximab). In the 17p deletion/TP53 mutation subgroup, zanubrutinib demonstrated the most favorable efficacy (HR 0.52, 95% CI 0.31-0.88 versus ibrutinib) with the highest SUCRA value (97%). For patients without these mutations, venetoclax plus rituximab was the most effective (HR 0.49, 95% CI..."

IO biomarker • Retrospective data • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • TP53

Clinical Characteristics, Treatment Strategies, and Outcomes for CLL Patients with BTK Mutation; A Single Center Study (ASH 2023) - "Twenty-three (76.7%) of the patients were on ibrutinib, while 7 (23.3%) were on acalabrutinib...Six patients (20.0%) continued on the same BTKi with addition of venetoclax, 10 (33.3%) patients were switched to venetoclax and immunotherapy (either obinutuzumab or rituximab), and 3 (10.0%) patients were started on single agent venetoclax...Three (10.0%) patients were taken to chimeric T cell receptor (CAR-T) cell therapy of which one patient had no response and was started on salvage treatment with duvelisib... Our results reveal that durable responses can be achieved by switching to venetoclax based regimens in patients with BTKi. Though the early results of the use of noncovalent BTKi in this setting aree encouraging, the durability of response is limited as new BTK mutations are selected and future therapeutic alternatives are needed for these subset of patients."

Clinical • IO biomarker • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • Richter's Syndrome • ASXL1 • BIRC3 • BTK • NOTCH1 • PLCG2 • SF3B1 • TET2 • TP53

Financial Toxicity and Quality of Life in Patients Taking Oral Therapy for Hematologic Malignancies (ASH 2023) - "MethodsWe used database query to identify patients at a midwestern, tertiary care, academic medical center who were 18 years or older and were prescribed Enasidenib, Ivosidenib, Venetoclax, Gilteritinib, Midostaurin, Ibrutinib, Acalabrutinib, Imatinib, Nilotinib, Ponatinib, Bosutinib, Duvelisib, or Idelalisib within the past 3 months. Financial stress and hardship were associated with worse satisfaction with QoL and worse experience of SE. Further study should define change in these features over time and interventions to mitigate distress."

Clinical • HEOR • Acute Myelogenous Leukemia • Chronic Lymphocytic Leukemia • CNS Disorders • Depression • Hematological Malignancies • Mood Disorders • Oncology • Oral Cancer • Psychiatry

A Phase I Study of Combination Duvelisib and Nivolumab in Patients With Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma, and Richter Transformation. (PubMed, Eur J Haematol) - No abstract available

Journal • P1 data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Richter's Syndrome

Dual PI3Kδ/γ inhibition enhances radiotherapy-induced antitumor immunity via macrophage-dependent cGAS-STING-type I interferon signaling. (PubMed, Biochem Biophys Res Commun) - "In the syngeneic CT26 model, dual PI3Kδ/γ inhibition (BR101801 or duvelisib), unlike selective PI3Kδ inhibition (idelalisib), synergized with RT (7.5 Gy) to suppress tumor growth and induce durable immune memory. Furthermore, blockade of the IFN-I receptor abolished CD8+ T cell infiltration and M2-like macrophage suppression, abrogating antitumor efficacy and confirming the requirement for IFN-I signaling. These findings identify macrophage-driven activation of the cGAS-STING-IFN-I axis as a key mechanism by which dual PI3Kδ/γ inhibition potentiates RT, providing a strong scientific rationale for its development as an immunomodulatory radiosensitizer."

Journal • Colorectal Cancer • Oncology • Solid Tumor • CD8 • CGAS • CXCL10 • PIK3CD • PIK3CG • STING

Secura Bio Presents Extended Follow Up Analyses from Phase 2 PRIMO Trial in Patients with Relapsed/Refractory peripheral T-cell lymphoma at the 2025 American Society of Hematology Meeting (GlobeNewswire) - "New extended analyses demonstrated there was no consistent impact on efficacy outcomes for patients related to number of prior lines of treatment. In patients with 1, 2, and ≥3 prior lines of therapy, outcomes were as follows, respectively: ORR was 29%, 66%, 49%; complete response (CR) was 18%, 52%, 32%; median duration of response (DOR) was 6.5, 11.7, 7.9 months; median progression-free survival (mPFS) was 1.9, 9.0, 3.0 months, and median overall survival (OS) was 30.2, 22.7, 7.3 months."

P2 data • Peripheral T-cell Lymphoma

Endpoint Exposure-Response Analyses in the Presence of Concurrent Dose Modification During Clinical Trials. (PubMed, Clin Pharmacol Ther) - "Using duvelisib as an exemplar, a drug known for frequent DMs due to Grade ≥ 3 infections, pneumonia, or transaminase elevations, we evaluated E-R relationships under three scenarios: ground truth, conventional E-R (based on planned dose exposures), and DM-adjusted E-R (accounting for AE-induced DMs and resultant exposure changes)...DM-adjusted E-R analyses better approximate the ground truth, especially for late-occurring AEs, but may introduce a risk of overcorrection of early-occurring AEs. These findings highlight the critical need to incorporate the timing and nature of AEs into E-R analyses to ensure robust interpretation, particularly in settings where DMs are frequent."

Journal • Infectious Disease • Pneumonia • Respiratory Diseases

Enantiomeric separation of duvelisib by Electrokinetic Chromatography. Application to the analysis of pharmaceutical formulations and determination in serum and wastewater samples previous μSPEed preconcentration. (PubMed, Talanta) - "This work presents, for the first time, the stereoselective determination of duvelisib in pharmaceutical, biological, and environmental matrices, and the first application of μSPEed to enhance the sensitivity of a chiral methodology. The proposed strategy constitutes a fast and green tool for the stereoselective analysis of duvelisib with application to pharmaceutical analysis, and environmental and clinical monitoring."

Journal • Oncology

Mechanistic Studies of Cytokine Release Syndrome (CRS) with Roles of Interferon-Gamma (IFN-g) and Tumor Necrosis Factor Alpha (TNF-α) While Maintaining CAR-T Function in Vitro (ASH 2023) - "In contrast to dasatinib which completely blocked both CRS and CART killilng (data not shown), no significant attenuation of CAR-T killing efficacy was found with any of these kinase inhibitors or the neutralizing antibodies...CRS (in vitro production of IL-6) was dependent on the presence of GM-CSF/IL-4 "primed" iDC and abolished by duvelisib while maintaining blinatumomab-induced Ramos killing (Fig 2)...Marked increase in secreted mouse IL-6 was observed which was completely inhibited by duvelisib, ruxolitinib, anti-IFNγ and anti-TNFα... We have developed in vitro CRS co-culture models using cells from both man and mouse and tested the role of multiple effector cell types including CART cells, CARMLNK cells, and CAR-iNK cells and multiple inhibitors on CRS and CART function in vitro. We show that JAK1/2 and PI3Kg/d kinase inhibitors as well as neutralizing antibodies to IFNγ and TNFα all block in vitro CRS without attenuating the anti-tumor efficacy of CAR-T..."

Cytokine release syndrome • IO biomarker • Preclinical • Hematological Malignancies • Hypotension • Oncology • CSF2 • IFNG • IL10 • IL4 • IL6 • TNFA

Dual-Targeted Therapy with Ruxolitinib Plus Duvelisib for T-Cell Lymphoma (ASH 2024) - "The combination is particularly active in TFH lymphomas and T-PLL as well as cases with evidence of JAK/STAT activation. Further expansion for TFH lymphomas and T-PLL is planned."

Adult T-Cell Leukemia-Lymphoma • Anemia • Cardiovascular • Cutaneous T-cell Lymphoma • Dermatology • Dyslipidemia • Follicular Lymphoma • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Hepatology • Herpes Zoster • Hypertension • Hypertriglyceridemia • Immunology • Infectious Disease • Leukemia • Leukopenia • Lymphoma • Mucositis • Mycosis Fungoides • Nephrology • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • Pneumonia • Prolymphocytic Leukemia • Respiratory Diseases • Septic Shock • T Cell Non-Hodgkin Lymphoma • T-Cell Large Granular Lymphocyte Leukemia • Thrombocytopenia • Varicella Zoster • ALK

Subsequent Treatment and Clinical Outcome Following Induction Therapy on a Phase II Study of Oral Azacitidine Plus CHOP for Peripheral T-Cell Lymphoma (PTCL) (ASH 2024) - P2 | "Subsequent salvage regimens for the 10 relapsed PTCL patients included : duvelisib single agent (n=1), duvelisib + romidepsin (n=2, one moved on to alloSCT), duvelisib plus ruxolitinib (n=1), romidepsin + BV followed by alloSCT (n=1), single agent sequences of romidepsin, bendamustine, duvelisib, followed by BV-DICE (n=1), romidepsin plus azacitidine sequenced with single agent bendamustine, followed by BV-DICE (n=1), high dose methotrexate-based regimen with modified MATRIX without rituximab for CNS relapse (n=1), phase 1 clinical trial (n=1), and palliation (n=1). The one patient with relapsed DLBCL was treated with R-DHAX 2 cycles, polatuzumab vedotin/bendamustine/rituximab 2 cycles, followed by CAR-T (Yescarta)...Subsequent treatments following relapses were notable for salvage sequences incorporating novel agents as well as allogeneic stem cell transplant, which may benefit to extend survival in this cohort. These preliminary response and survival outcome data..."

Clinical • Clinical data • IO biomarker • P2 data • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • DNMT3A • TET2 • TNFRSF8

Clinical Characteristics, Treatment Patterns, and Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Refractory to Covalent Bruton's Tyrosine Kinase Inhibitor (BTKi) and Exposed to B-Cell Lymphoma 2 Inhibitor (BCL2i) (ASH 2023) - "The therapies received in the first line after BTKi and BCL2i were allogeneic HSCT (4 patients), duvelisib (3 patients), oral CDK9i (2 patients), and 1 patient each with CAR-T, anti-CD20 bispecific antibody, alemtuzumab, vecabrutinib, zanubrutinib; and for patients with RT: venetoclax plus rituximab with anthracycline chemotherapy (2 patients), PI3Ki/PD-1 (1 patient), duvelisib (1 patient) (Figure 1). Patients with CLL/SLL who were failed by BTKi and BCL2i treatment have poor prognosis. Overall response rates to treatment immediately after BTKi and BCL2i treatment are low among doubly refractory patients. More effective treatments are needed to address the unmet therapeutic needs of CLL/SLL patients who are refractory to both BTKi and BCL2i."

Clinical • IO biomarker • B Cell Lymphoma • Bone Marrow Transplantation • Chronic Lymphocytic Leukemia • Leukemia • Lymphoma • Oncology • Richter's Syndrome • Small Lymphocytic Lymphoma • BCL2 • IGH • PD-1 • TP53

Novel Pi3kδ Inhibitor Roginolisib Synergizes with the Bcl-2 Inhibitor Venetoclax in Hematological Malignancies (ASH 2023) - "To further validate this finding, the combination of roginolisib with venetoclax or with another bcl-2 inhibitor S55746 was tested in a broad range of lymphoma cell lines including GRANTA519, JVM2, SP49 (MCL); FARAGE, TMD8 (diffuse large B cell lymphoma); MEC1 (chronic lymphocytic leukemia); MJ (cutaneous T cell lymphoma); and YT (NK lymphoma)...Other BCRi such as idelalisib, duvelisib and acalabrutinib were used at 5 μM concentrations as positive controls...In addition, roginolisib synergized with venetoclax in lymphoma cell lines and CLL patient samples. Our data support extending this combination strategy to clinical trials in hematological malignancies."

IO biomarker • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Cutaneous T-cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor • T Cell Non-Hodgkin Lymphoma • BCL2L1 • MCL1 • PIK3CD